Precision oncology: neither a silver bullet nor a dream.

摘要: Precision oncology is not an illusion, nor it the magic bullet that will eradicate all cancers. simply another weapon in our growing armament against cancer. Rather than honing on failures of a relatively young field, one should advocate for integrating its successes into widespread clinical practice, especially indications, such as: ABL, ALK, BRAF, BRCA1, BRCA2, EGFR, KIT, KRAS, PDGFRA, PDGFRB, ROS1, BCR-ABL, FLT3 and where aberrations have been shown to alter responses US FDA approved drugs - is, level 1 data. Moreover, truly assess promise precision oncology, we must first begin by defining expectations this field. Importantly, recognize conception arose as antithesis 'one-size fits all' cancer therapeutics approach. Consequently, tools used evaluating these conventional, large-scale trials, are directly transferable assessing nonconventional, smaller-scale trials needed oncology. Hence, thorough vetting tool trade, reassessing well current trial designs end point measurements. most targeted therapy approaches their infancy, with only monotherapy being assessed combination therapies likely necessary fulfill